NCT06281951 Nebulized Fentanyl in Healthy Volunteers
| NCT ID | NCT06281951 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University Hospital, Rouen |
| Condition | Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-04-26 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2024-04-26 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pain constitutes the predominant motive prompting individuals to seek emergency medical attention, accounting for 80% of admissions to emergency departments. Presently, it is imperative to employ expeditious and efficacious analgesia-sedation methodologies, obviating the necessity for intravenous administration, while ensuring the secure delivery of pharmaceutical agents. The objective of this study is to assess the feasibility and comfort of nebulized intranasal or facial aerosol administration of Fentanyl through the implementation of a pharmacokinetic/pharmacodynamic (PK/PD) study
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and \< 68 years * BMI between 19 and 29 kg/m² * Affiliation to a social security scheme * Adult who has read and understood the information letter and signed the consent form * Woman capable of procreating (a woman is considered capable of procreating, i.e. fertile, after menarche and until she becomes menopausal, unless she is definitely sterile ) having very effective contraception (combined hormonal contraception (containing estrogens and progestins) associated with inhibition of ovulation, progestin-only hormonal contraception associated with inhibition of ovulation, intrauterine device, hormone-releasing intrauterine system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence) for 1 year and a negative urine pregnancy test at inclusion and during the duration of the study. * Woman definitely surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy). Postmenopausal woman: The postmenopausal state is defined by the absence of periods for 12 months without any other medical cause. Exclusion Criteria: * Weight \< 50 kg * Taking long-term painkillers or narcotics * Sharp pain * Stable chronic pain (\>3 months, with or without long-term treatment) * Known chronic pathology stabilized or decompensated (hypertension, renal, cardiac, hepatic insufficiency, etc.) * Stable or decompensated chronic respiratory pathology * Chronic neuropsychiatric pathology likely to modify the pain threshold * Long-term treatment with an action on the nervous system such as respiratory depression: benzodiazepines, neuroleptics, agonist/antagonist of the opioid system * Treatment or toxicant whose association is not recommended with fentanyl (alcohol, cannabis, etc.) * Central nervous system modulator treatment * Pathologies blocking the pupillary response: Claude-Bernard-Horner syndrome, Adie syndrome, Argyll-Robertson pupil, senile miosis, dysautonomic neuropathy (advanced diabetes, systemic amyloidosis), cataract * Treatment responsible for fluctuation in PUAL measurements: parasympathetic modulators (clonidine, dexmedetomidine, droperidol, metoclopramide) * No-indication to FENTANYL PIRAMAL 100µg/2mL, solution for injection in ampoule * No-indication to PROAMP SODIUM CHLORIDE 0.9%, solution for injection * Ongoing treatment with nasal vasoconstrictors * Peripheral oxygen saturation less than 93% * Alteration of cognitive state: comprehension disorder, language disorder, memory disorder, confusion * Deaf or mute patient * Usual heart rate such as HR\< 40 bpm and/or hypotension with systolic blood pressure SBP\< 100 mm Hg * Atrioventricular block on ECG * History of cataract surgery * Confirmed or suspected covid 19 / active flu infection less than 15 days old * Allergy to plastic * Pregnant or parturient or breastfeeding woman or proven absence of contraception * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship * Person participating in research participating in another trial / having participated in another trial within 2 weeks * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06281951 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 68 Years, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06281951 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06281951 currently recruiting?
Yes, NCT06281951 is actively recruiting participants. Contact the research team at cassandre.follet@chu-rouen.fr for enrollment information.
Where is the NCT06281951 trial being conducted?
This trial is being conducted at Rouen, France.
Who is sponsoring the NCT06281951 clinical trial?
NCT06281951 is sponsored by University Hospital, Rouen. The trial plans to enroll 20 participants.